Literature DB >> 29310493

Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.

B Glintborg1,2, T Kringelbach3, N Bolstad4, D J Warren4, G Eng5, I J Sørensen1,6, A G Loft7, O Hendricks8, Imj Hansen9, A Linauskas10, H Nordin5, S Kristensen11, H Lindegaard12, D V Jensen2, G L Goll13, E Høgdall14, J Gehin15, C Enevold16, C H Nielsen16, N S Krogh17, J S Johansen6,14,18, M L Hetland1,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29310493     DOI： 10.1080/03009742.2017.1376110

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  4 in total

1.  The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.

Authors:  Thomas Bo Jensen; Dorthe Bartels; Eva Aggerholm Sædder; Birgitte Klindt Poulsen; Stig Ejdrup Andersen; Mette Marie H Christensen; Lars Nielsen; Hanne Rolighed Christensen
Journal:  Eur J Clin Pharmacol       Date:  2019-11-01       Impact factor: 2.953

2.  Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.

Authors:  G L Goll; K K Jørgensen; J Sexton; I C Olsen; N Bolstad; E A Haavardsholm; K E A Lundin; K S Tveit; M Lorentzen; I P Berset; B T S Fevang; S Kalstad; K Ryggen; D J Warren; R A Klaasen; Ø Asak; S Baigh; I M Blomgren; Ø Brenna; T J Bruun; K Dvergsnes; S O Frigstad; I M Hansen; I S H Hatten; G Huppertz-Hauss; M Henriksen; S S Hoie; J Krogh; I P Midtgard; P Mielnik; B Moum; G Noraberg; A Poyan; U Prestegård; H U Rashid; E K Strand; K Skjetne; K A Seeberg; R Torp; C M Ystrøm; C Vold; C C Zettel; K Waksvik; B Gulbrandsen; J Hagfors; C Mørk; J Jahnsen; T K Kvien
Journal:  J Intern Med       Date:  2019-04-12       Impact factor: 8.989

Review 3.  The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.

Authors:  Anita Afzali; Daniel Furtner; Richard Melsheimer; Philip J Molloy
Journal:  Adv Ther       Date:  2021-03-21       Impact factor: 3.845

4.  Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study.

Authors:  Tina Marie Kringelbach; Bente Glintborg; Estrid V Hogdall; Julia Sidenius Johansen; Merete Lund Hetland
Journal:  BMJ Open       Date:  2018-02-01       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.